App-Quantinova.ai

Real-World Data on the Incidence and Management of Blinatumomab Toxicities in Adult Patients with Minimal Residual Disease and Relapsed or Refractory Acute Lymphoblastic Leukemia

Rebecca Farley - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Blinatumomab

Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study

Fadi Haddad - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Cyclophosphamide

Updated Outcomes in Adult Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Using Tyrosine Kinase Inhibitors Combined with the Modified University of Southern California (USC ALL) Regimen without Peg-Asparaginase in the Era of Novel Agents

Vincent Louie Louie Mendiola - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

PEG-asparaginase

A Phase 1, First-in-Human, Dose-Escalation Study of MGD024, a CD123 x CD3 Bispecific Dart® Molecule, in Patients with Relapsed or Refractory CD123-Positive (+) Hematologic Malignancies

Eric S. Winer - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

Tocilizumab

From Generic RNA-Based MRD Assessment Towards Patient-Specific Genomic (DNA-based) MRD in AML and Other Non-B Cell Acute Leukemia

Edwin Sonneveld - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute lymphoblastic leukemia

N/A

Relative Telomeric Length of Bone Marrow Cells at Diagnosis and Its Association with Minimal Residual Disease in Juvenile Acute Lymphoblastic Leukemia

Paula Cristina Galati - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

The Bacterial Chaperone High-Temperature Protein G (HtpG) Decreases in Abundance with Induction Therapy in Children with Acute Lymphoblastic Leukemia

Emma MacDonald - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Chemotherapy or Hematopoietic Stem Cell Transplantation in B-Lineage Acute Lymphoblastic Leukemia Patients Based on IKZF1 and MRD Status

Shiyu Deng - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Allopurinol

Comparison of Dexamethasone Versus Prednisolone Prephase in Induction Therapy of Pediatric Acute Lymphoblastic Leukemia: A Single-Center, Randomized Controlled Study from India

Anamika Bakliwal - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Dexamethasone

A Clinical Laboratory-Oriented Targeted RNA-Seq System Accurately and Efficiently Detected Various Fusion Gene Mutations in Philadelphia Chromosome-like Acute Lymphoblastic Leukemia

Yong Jun Choi - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute lymphoblastic leukemia

N/A

Patterns and Prognostic Impact of CNS Infiltration in Adults with Newly Diagnosed Acute Lymphoblastic Leukemia

Luiza Lapolla Perruso - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute lymphoblastic leukemia

Allopurinol

Digital Droplet PCR for Minimal Residual Disease Assessment in Philadelphia-Positive Acute Lymphoblastic Leukemia Using IG/TR Genes and BCR/ABL1 as Markers. Preliminary Results of a Comparative Analysis

Marco Beldinanzi - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Ponatinib

Impact of Antibiotic Use for Febrile Neutropenia on Gut Microbiome Phyla in Children with Leukemia and Lymphoma

Jane MacDonald - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute lymphoblastic leukemia

vancomycin capsule

Initiation and Implementation of Infusional Chemotherapy As a Base Regimen for Increased Risk Lymphoid Malignancy in an Inner-City Academic Institution

Walter JR Quan - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Cyclophosphamide

A Rare Case of Spontaneous Tumor Lysis Syndrome As a Consequence of Forgone Treatment in Multiple Myeloma

Kathleen Humkey - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Acute lymphoblastic leukemia

Cyclophosphamide

Predicting Response of CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL) and Aggressive Non-Hodgkin Lymphoma (NHL) in ACIT001/EXC002, a Phase Ib Clinical Trial

Bindu Thapa - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute lymphoblastic leukemia

Interferon Gamma

Development of Humanized CD19-Chimeric Antigen Receptor for B Cell Malignancy

Vibhuti Vyas - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute lymphoblastic leukemia

Interferon Gamma

Treatment Profile of CAR-T Cell Therapy Induced Cytokine Release Syndrome and Neurotoxicity: Insights from Real-World Evidence

Kyeryoung Lee - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

Dexamethasone

Early Cytopenias and Infections Following Chimeric Antigen Receptor T-Cell Therapy: A Single Center Experience

Mary McGann - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

Filgrastim

Blinatumomab or Inotuzumab Ozogamicin As Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis

Ali Unal - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

Inotuzumab ozogamicin

Filters

2187 Abstracts